17,261 trials
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 12 — -0.99; -1.33 percentage of A1C — p=0.10
Ductal Breast Carcinoma in Situ · Lobular Breast Carcinoma in Situ · Male Breast Cancer
Primary: PUFA Levels in Normal and Metastatic Breast Tissue — 60.986; 72.762; 3.232; 3.505 ug/ml
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 12 — -0.35; -0.60; -0.84; -0.73 percentage of A1C — p=0.07
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 3.94; 4.39 Months
Type 1 Diabetes Mellitus
Primary: Percent Change From Baseline in Total Daily Bolus Amount of Exogenous Insulin Required Calculated Over Days 3 to 27 (Treatment Outpatient Period) — -46.32; -7.00; -32.14…
Neuroblastoma · Sarcoma
Primary: Objective Response Rate
Hemodialysis-Induced Symptom · Mitochondrial Diseases
Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds
Carcinoma, Squamous Cell of Head and Neck
Primary: Comparison of Progression Free Survival (PFS) Between Treatment Groups Using irRECIST and Evaluated by Independent Radiology. — 185; 181 days — p=0.266
Intermittent Explosive Disorder
Primary: Safety and Tolerability — 28; 21; 0; 0 participants
Metastatic Castration-Resistant Prostate Cancer
Primary: Median Time on Treatment — 11 weeks
Follicular Lymphoma
Primary: Number of Participants With Overall Response Rate (ORR) — 0; 0; 0; 0 participants
Anemia · Cancer Fatigue · Chronic Lymphocytic Leukemia
Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…
Parenteral Nutrition Associated Liver Disease PNALD · Cholestasis
Primary: Number of Patients With Progression to Small Bowel Transplantation. — 19 Participants
Chlamydial Infection
Primary: Proportion of Participants Experiencing Treatment Failure After Treatment With Azithromycin for Uncomplicated Chlamydia Trachomatis (CT) in Males With and Without…
Influenza · Influenza Vaccines
Primary: Number of Subjects With H5N1 Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value — 0; 0; 0; 0 Participants